Cholesterol-lowering statins, such as Pfizer's Lipitor and AstraZeneca's Crestor, don't raise the risk of cancer, according to an analysis of 15 statin studies with nearly 100,000 participants. U.S. researchers found that the drugs reduced levels of LDL or "bad" cholesterol by 40 points on average in the trials without affecting total cancer risk. The findings are expected to address concerns that arose after previous studies linked statins to elevated cancer risk.

Full Story:

Related Summaries